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Extracellular cues play crucial roles in the 
transcriptional regulation of tissue-specific 
genes, but whether and how these signals 
lead to chromatin remodeling is not 
understood and subject to debate. Using 
chromatin immunoprecipitation (ChIP) 
assays and mammary-specific genes as 
models, we show here that extracellular 
matrix (ECM) molecules and prolactin 
cooperate to induce histone acetylation and 
binding of transcription factors and the 
SWI/SNF complex to the ß- and ?-casein 
promoters. Introduction of a dominant 
negative Brg1, an ATPase subunit of 
SWI/SNF complex, significantly reduced 
both ß- and ?-casein expression, suggesting 
that SWI/SNF-dependent chromatin 
remodeling is required for transcription of 
mammary-specific genes. ChIP analyses 
demonstrated that the ATPase activity of 
SWI/SNF is necessary for recruitment of 
RNA transcriptional machinery, but not for 
binding of transcription factors or for 
histone acetylation. Co-
immunoprecipitation analyses showed that 
the SWI/SNF complex is associated with 
STAT5, C/EBPß, and glucocorticoid 
receptor (GR). Thus, ECM- and prolactin-
regulated transcription of the mammary-
specific casein genes requires the concerted 
action of chromatin remodeling enzymes 
and transcription factors. 
Differentiated function of mammary epithelial 
cells is regulated by signals from both ECM 
and lactogenic hormones (1-3). The gene 
encoding the milk protein, ß-casein, has been 
used widely as a marker for functional 
differentiation of MECs. We and others have 
shown that in both primary mouse mammary 
epithelial cells and immortalized mammary 
epithelial cell lines (4-6), transcription of ß-
casein requires signals from both laminin-111 
(previously referred to as laminin-1) and 
prolactin (1,2,7-10). A number of transcription 
factors, including STAT5, C/EBPß, and GR, 
have been shown to be involved in this 
process [reviewed in (7)].  
Modulation of chromatin structure by histone 
modifications and ATP-dependent remodeling 
has been implicated in cell differentiation and 
transcriptional control of tissue-specific and 
inducible genes (11-13). Histone modifying 
enzymes are believed to be recruited to 
promoter regions through their association 
with transcription factors, and are critical for 
tissue-specific gene expression and functional 
differentiation of specific cell types (14,15). 
Histone acetylation is a dynamic process and 
is regulated by histone acetyltransferases 
(HATs) and histone deacetylases (HDACs) 
(16). The mapping of global histone 
acetylation patterns has demonstrated that 
chromatin accessibility and gene expression 
are correlated with histone hyperacetylation of 
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promoters and other cis-elements (17,18). The 
p300 HAT cooperates with STAT5 to enhance 
exogenous ß-casein promoter activity in COS 
cells, indicating that histone acetylation may 
play a role in ß-casein transcription (19). 
Trichostatin A (TSA), an inhibitor of HDAC, 
was shown to activate the bovine casein ECM-
response element (BCE-1) in an ECM-
independent fashion in a mouse epithelial cell 
line in tissue culture plastic, but surprisingly 
the same treatment inhibited the endogenous 
ß-casein transcription (20,21). Therefore, the 
role of histone acetylation in mammary-
specific gene transcription has not been 
elucidated. 
ATP-dependent chromatin remodeling 
SWI/SNF complexes are involved in cellular 
differentiation and tissue-specific transcription 
(14,22,23). Mammalian cells contain at least 
two SWI/SNF-like complexes that share a 
number of subunits, but are distinguished from 
one another by their ATPase subunits, Brg1 
and Brm1 (24). Introducing a dominant 
negative Brg1 (DN-Brg1) or Brm1 into mouse 
NIH-3T3 fibroblasts completely abrogated 
MyoD-mediated muscle differentiation,  and 
failure to induce transcription of the muscle-
specific myogenin gene was correlated with 
inhibition of chromatin remodeling in the 
promoter region (14). To date, two different 
mechanisms have been described for 
recruiting SWI/SNF complexes to tissue-
specific genes. Transcription factors, such as 
GR and C/EBPß, have been shown in 
mammalian cells to recruit the SWI/SNF 
complex to cis-elements to activate specific 
gene transcription (23,25-27). Alternatively, 
the ATPase subunits of SWI/SNF contain 
bromodomains, which can bind directly to 
acetylated histone tails in vitro (28,29). Thus, 
acetylated histones in a particular chromatin 
region may contribute to the recruitment of 
SWI/SNF complexes to specific genes. 
Using the b- and g-casein genes as models, 
here we investigate how ECM and prolactin 
regulate the activity of STAT5 and C/EBPß, 
and we elucidate the roles of histone 
acetylation and ATP-dependent chromatin 
remodeling in expression of these mammary 
specific genes. The findings from this study 
indicate that the precise regulation of 
mammary-specific gene transcription depends 
not only on transcription factor activation and 
histone modifications, but also on ATP-
dependent chromatin remodeling. 
EXPERIMENTAL PROCEDURES 
Reagents and antibodies - Antibodies against 
acetylated H4 and acetylated H3 were from 
Upstate Biotechnology. The H3 antibody was 
from Abcam. The STAT5 antibody was from 
R&D Systems, and those against C/EBPß, 
RNA polymerase II, GR, and Brg1 were from 
Santa Cruz Biotechnology. Anti-Flag antibody 
(M2) was from Sigma. Protein A agarose 
beads were obtained from Upstate 
Biotechnology. Phosphatase inhibitor cocktail 
and protease inhibitor cocktail were from 
Calbiochem. 
Cell culture and transfections - EpH4 cells 
were derived from IM-2 cells, originally 
isolated from the mammary tissue of a mid-
pregnant mouse (4,5). EpH4 cells were 
maintained in growth medium consisting of 
DMEM/F12 (UCSF cell culture facility) 
supplemented with 2% fetal bovine serum 
(GIBCO-BRL), 50 mg/ml gentamycin (UCSF 
cell culture facility), and 5 mg/ml insulin 
(Sigma). Cells were plated at a density of 
10000/cm2 in growth medium and allowed to 
attach for 16-24 hours. The cells were cultured 
in DMEM/F12 medium supplemented with 5 
mg/ml insulin and 1 mg/ml hydrocortisone 
(Sigma) (GIH medium). In other experiments, 
3 mg/ml prolactin, 2% laminin-rich ECM 
(lrECM; Matrigel®, BD Biosciences), 3 mg/ml 
prolactin plus 2% lrECM [or 100 mg/ml 
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laminin-111 (Trevigen)] were added in the 
GIH medium (1).  
EpH4 cells were seeded onto 35 mm dishes 
and transfected using Lipofectamine 2000 
(Invitrogen) with the following plasmids: 3 mg 
of DN-Brg1 plasmid (14) (a kind gift from Dr. 
Anthony N. Imbalzano, University of 
Massachusetts Medical School, MA, USA.), 1 
mg of pTet-tak, which encodes the tet-VP16 
regulator, and 0.4 mg of pNeo plasmid. 
Twenty four hours after transfection, 400 
mg/ml geneticin (Sigma) was added to the 
media, which were changed every 48 hours 
for 10 days. The resulting stably-transfected 
clones were washed twice with growth 
medium and incubated in the presence or 
absence of 0.5 mg/ml tetracycline for four days. 
Positive clones expressing a 200 kDa Flag-tag 
protein in the absence, but not presence of, 
tetracycline were identified by western blots 
analysis. 
Promoter reporter plasmid construction and 
luciferase assays - A 340 bp DNA fragment 
containing the ß-casein promoter region was 
amplified from mouse genomic DNA using 
the following primer sequences: forward 
primer 5’CGA GGT ACC TTC ATA ACT 
GAG GTT AAA GCC-3’; reverse primer 
5’CAG AAG CTT GTC CTA TCA GAC TCT 
GTG AC-3’. PCR product was digested with 
Hind III and Kpn I, and subsequently cloned 
into a reporter vector pGL3 (Promega). EpH4 
cells were co-transfected with pGL-casein and 
pNeo plasmid (1:10). Stably transfected cells 
were isolated by G418 selection and cultured 
in GIH medium for 2 days in the presence of 
different inducer. Following induction, equal 
amounts of cell lysates were assayed for 
luciferase activity. 
Western blot and co-immunoprecipitation (co-
IP) -Western blot experiments were performed 
as previously described (30). Total and 
nuclear protein were extracted from EpH4 
cells or nuclei using radio-
immunoprecipitation buffer [50 mM Tris (pH 
7.4), 30 mM NaCl, 1% (v/v) NP40, 1% (w/v) 
deoxycholate, 0.1% (w/v) SDS, protease 
inhibitor cocktail, and phosphatase inhibitor 
cocktail]. After sonication, insoluble material 
was removed by centrifugation at 15,000 g for 
10 min. Proteins (20 mg) from each sample 
were subjected to SDS gel electrophoresis and 
then transferred to nitrocellulose membrane 
(Schleicher & Schuell). The membrane was 
subsequently blocked in TBST buffer [50 mM 
Tris (pH 8.0), 150 mM NaCl, 0.1% (v/v) 
Tween 20] containing 5% Carnation nonfat 
dried milk, and incubated in blocking buffer 
containing primary antibody. All blots were 
further incubated in blocking buffer 
containing horseradish peroxidase-conjugated 
secondary antibodies and subjected to 
enhanced chemiluminescence (ECL) using the 
SuperSignal chemiluminescent substrate 
(Pierce, Rockford, IL). 
Cells transfected with DN-Brg1 were cultured 
in the presence or absence of tetracycline for 2 
days in GIH medium containing prolactin and 
lrECM, and nuclei were isolated using a 
nucleus isolation kit (Sigma). The nuclei were 
resuspended and sonicated in lysis buffer (10 
mM Tris-HCl, pH7.5; 150 mM NaCl; 2 mM 
EDTA; 0.5% Triton X-100; protease inhibitor 
cocktail) and centrifuged at 15000 g for 10 
min. After centrifugation, 40 µl of agarose 
beads conjugated to an anti-Flag M2 antibody 
were added to the supernatant of each sample 
and incubated with shaking at 4°C for 4 hours 
The agarose beads were washed with rinsing 
buffer (50 mM Tris-HCl, pH7.5; 150 mM 
NaCl; 0.05% Triton X-100). Agarose-
associated protein complexes were eluted 
using SDS loading buffer and analyzed by 
western blots. 
RT-PCR and Real Time PCR - Total RNA was 
extracted from cells with Trizol reagent 
(Invitrogen). cDNA was synthesized using 
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Superscript first strand synthesis kit 
(Invitrogen) from 1 µg RNA samples. One 
microliter of cDNA was used as a template for 
PCR and real time PCR. The glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was 
amplified and used as a loading control. The 
following primers were used to amplify ß-
casein, ?-casein, lactoferrin and GAPDH 
cDNA sequences: forward primer of the ß-
casein gene 5'-GCT CAG GCT CAA ACC 
ATC TC-3' and reverse primer 5'-TGT GGA 
AGG AAG GGT GCT AC-3'; forward primer 
of the ?-casein gene: 5'-CCC AGG AGT CTT 
CCT TTT CC-3' and reverse primer 5'-GGA 
AAC CAC GAA GAA ACC AA-3'; forward 
primer of the lactoferrin gene: 5'-AGT GAG 
GAG AAG CGC AAG TGT G-3' and reverse 
primer 5'-AGC CCC AGT GTA GCC TTG 
GTA T-3'; forward primer for GAPDH gene 
5’CCC CTG GCC AAG GTC ATC CAT 
GAC-3’ and reverse primer 5’CAT ACC 
AGG AAA TGA GCT TGA CAA AG-3’. 
Quantitative real-time PCR analysis was 
performed with the Lightcycler System 
(Roche) using the Lightcycler FastStart DNA 
Master SYBR Green I kit (Roche) (31).  The 
following Lightcycler PCR amplification 
protocol was used: 95°C for 10 min (initial 
denaturation), and 45 amplification cycles 
(95°C for 5 s, 60°C for 10 s, 72°C for 5 s). 
Amplification was followed by melting curve 
analysis to verify the presence of a single PCR 
product. 
Chromatin immunoprecipitation - The ChIP 
assay was performed based on the Upstate 
Biotechnology ChIP protocol (32) with a few 
modifications. Cellular components were 
cross-linked by adding formaldehyde to a final 
concentration of 1% and incubated at room 
temperature for 10 minutes. The cross-linking 
reaction was stopped by adding glycine to a 
final concentration of 125 mM. Nuclei were 
isolated with a nucleus isolation kit and 
resuspended in ChIP lysis buffer (1% SDS, 
10mM EDTA, 50 mM Tris-HCl pH8.0) 
containing protease inhibitor cocktail. The 
nuclei were then sonicated to shear DNA to 
lengths between 200 and 1000 bp. The 
sonicated lysates were diluted to an OD260 of 2 
units per ml with ChIP dilution buffer and 
incubated with 60 µl of protein A-conjugated 
agarose beads to reduce non-specific binding. 
Primary antibodies were added to the pre-
cleared supernatant fraction and incubated 
from 5 hour to overnight at 4ºC with rotation. 
Protein A-conjugated agarose beads (50 µl) 
were then added to the samples for one hour, 
and the protein-DNA complexes were eluted 
from the protein A agarose by incubation in 
250 µl elution buffer (1% SDS, 0.1M 
NaHCO3). Protein-DNA cross links were 
reversed by heating at 65ºC for 5 hours. The 
immunoprecipitated DNA was 
phenol/chloroform extracted and ethanol-
precipitated in the presence of 15 mg of linear 
polyacrylamide, an inert carrier. The isolated 
DNA was then analyzed by semi-quantitative 
PCR using the following primers: ß-casein 
promoter forward primer 5’GTC CTC TCA 
CTT GGC TGG AG-3’ and reverse primer 
5’GTG GAG GAC AAG AGA GGA GGT-3’; 
Amylase promoter forward primer 5’ TCA 
GTT GTA ATT CTC CTT GTA CGG-3’ and 
reverse primer 5’CCT CCC ATC TGA AGT 
ATG TGG GTC-3’; ?-casein promoter 
forward primer 5’AAA CAG GTG AGT CTG 
CCT TCA-3’ and reverse primer 5’CCA AAT 
GGA AGA CGA GAG GA-3’. 
Statistics - All data analysis was performed 
using Sigma Plot. Bar graphs represent mean 
± standard error of the mean (SEM).   
RESULTS 
Expression of mammary-specific genes 
depends on signals from both lactogenic 
hormones and ECM molecules; for ß-casein, 
the relevant ECM molecule is laminin-111 
(2,9,10). Using EpH4, an epithelial cell line 
derived from normal mouse mammary gland 
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(4,5), we observed that both ß- and ?-casein 
mRNA levels were highly upregulated in 
response to prolactin and lrECM treatment 
(Fig. 1A); expression correlated with 
significant changes in cellular morphology as 
shown previously for ß-casein (3). 
Furthermore, consistent with previous studies 
(1,30), we established that laminin-111 was 
indeed the lrECM constituent that induced ß-
casein expression in EpH4 cells (data not 
shown).  
The mouse ß-casein promoter contains 
binding sites for STAT5 and C/EBPß, and 
half-sites of the palindromic glucocorticoid 
response element (GRE) (33-35). To 
determine whether ECM and prolactin directly 
induce transcriptional activation of the ß-
casein promoter, we amplified and cloned the 
promoter region from -340 to -1 into a 
luciferase reporter vector and stably 
transfected the reporter plasmid into EpH4 
cells. Luciferase activity was dramatically 
induced in the transfected cells after treatment 
with lrECM and prolactin (Fig. 1B), indicating 
that the ß-casein promoter is transcriptionally 
activated in these cells. Consistent with the 
PCR results, neither prolactin nor lrECM 
alone could appreciably enhance promoter 
activity. STAT5 and C/EBPß binding sites 
were also identified in the bovine ß-casein 
ECM-response element, BCE-1 (20). To 
determine whether these two factors regulate 
ECM- and prolactin- induced expression of 
the endogenous ß-casein gene, total and 
nuclear lysates of EpH4 cells were analyzed 
by western blotting. Although the total level 
of STAT5 did not change, the levels of 
phosphorylated STAT5 and its nuclear 
translocation increased after combined 
treatment with lrECM and prolactin. However, 
neither treatment alone could induce these 
changes (Fig. 1C, 1D).  Total cell and nuclear 
levels of C/EBPß remained unchanged after 
the treatments (Fig. 1C, 1D).  
To determine whether STAT5 and C/EBPß 
become associated with the ß-casein promoter 
after ECM and prolactin treatment, we 
performed ChIP assays. Addition of these two 
ligands significantly increased the association 
of STAT5 and C/EBPß with the ß-casein 
promoter, whereas the interaction between the 
promoter and GR remained at the control level 
(Fig. 2A). The promoter of the b-amylase 
gene, which is not expressed in mammary 
epithelial cells, was included as a negative 
control and was not detected in any of the 
ChIP samples (data not shown). Thus, 
exposure of EpH4 cells to lrECM and 
prolactin increases both STAT5 levels in the 
nucleus, and the binding of this factor and 
C/EBPß to the ß-casein promoter. We also 
found that treatment with prolactin and lrECM 
moderately enhanced the binding of Brg1, the 
ATPase subunit of SWI/SNF complex, to the 
ß-casein promoter in EpH4 and primary 
mammary epithelial cells (Figure 2A and 
supplemental Figure 1). Analysis of the DNA 
immunoprecipitated with a RNA polymerase 
II antibody showed an increased association of 
this protein with the ß-casein promoter in 
response to treatment with lrECM and 
prolactin (Fig 2A).  
Binding sites of STAT5 and C/EBPß were 
identified in promoters of other milk protein 
genes, such as ?-casein (36). We asked 
whether ?-casein wae regulated similarly to b-
casein. The association of these factors with 
the ?-casein promoter was determined by 
ChIP assays. We found that treatment with 
prolactin and lrECM enhanced binding of 
STAT5 and C/EBPß, and increased Brg1 and 
RNA Polymerase II levels in the promoter 
region of ?-casein gene (Fig. 2B). The mouse 
casein genes cluster at a single gene locus on 
chromosome 5 in this order: a, b, ?, d, and ? 
(37), and the expression of casein genes is 
coordinately regulated during pregnancy and 
lactation (38). Thus, the binding of these 
transcription factors and the chromatin 
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remodeling complex together appears to 
activate the entire gene locus.  
We showed above that treatment with lrECM 
and prolactin induced the recruitment of 
transcription factors and the SWI/SNF 
complex to the ß-casein promoter. To 
determine whether ECM and prolactin control 
these events separately or cooperatively, we 
performed ChIP analysis after cells were 
treated either singly or with both agents. We 
found that STAT5 bound to the ß-casein 
promoter in cells treated with both lrECM and 
prolactin, but treatment with either component 
alone failed to induce appreciable binding (Fig. 
2C). These results are consistent with the 
western data showing that nuclear 
translocation of STAT5 depends on both the 
ECM and hormonal signals (Fig. 1D). 
Combined lrECM and prolactin treatment also 
induced binding of C/EBPß to the ß-casein 
promoter (Fig. 2C). Recruitment of Brg1 and 
RNA polymerase II in the ß-casein promoter 
required also both lrECM and prolactin (Fig. 
2C). These results establish that ECM 
cooperates with prolactin to induce the 
binding of transcription factors as well as the 
transcriptional machinery to the ß-casein 
promoter.  
Previously, we showed that treatment with 
histone deacetylase inhibitors could partially 
substitute for lrECM in activating a stably 
integrated bovine ECM-response element 
(BCE-1) in a mammary epithelial cell line 
(CID-9), suggesting that histone acetylation 
may play a role in transcriptional regulation of 
this enhancer (20). Surprisingly, however, the 
same treatment was later shown to inhibit 
transcriptional activation of the endogenous ß-
casein gene (21). Here we sought to determine 
whether histone acetylation is involved in 
transcriptional regulation of the endogenous 
ß-casein gene. ChIP assays using antibodies 
against acetylated histone H3 and H4 
demonstrated enhanced histone acetylation in 
the ß-casein promoter, but not the ß-amylase 
promoter, in response to treatment with 
lrECM and prolactin (Fig 3A). In addition, 
neither lrECM nor prolactin alone induced 
histone acetylation in the ß-casein promoter 
(data not shown), confirming that the 
cooperation between the two signals is 
important. 
To determine whether the increase of 
acetylated histone in the ß-casein promoter 
was sufficient to induce transcription of the 
endogenous gene, EpH4 cells were treated 
with TSA in the presence or absence of ECM 
and prolactin. ChIP data showed that the 
levels of acetylated histone H4 (AcH4) 
appreciably increased in the ß-casein promoter 
(Fig. 3B). Quantitative PCR showed, however, 
that the level of ß-casein mRNA was 
increased by only 1.6 fold in undifferentiated 
cells after TSA treatment; the levels of both 
total and phosphorylated STAT5, C/EBPß, 
and GR did not change (Fig. 3C, 3D). In the 
functionally differentiated cells that were 
cultured with prolactin and lrECM, TSA 
treatment significantly suppressed the 
induction of ß-casein expression. Western blot 
analysis showed that phosphorylated STAT5 
levels decreased in TSA treated cells, 
suggesting that this inhibition may be due to 
an indirect effect of TSA on STAT5 
phosphorylation (Fig. 3C, 3D). These results 
now clarify previous contradictions and 
indicate that histone acetylation alone is not 
sufficient to induce transcription of the 
endogenous ß-casein gene above the basal 
level.  
A point mutation in the ATP-binding site of 
Brg1 was shown to abolish its ATPase activity, 
and produce a dominant negative effect on the 
chromatin remodeling function of the 
SWI/SNF complex (39). To examine whether 
this ATPase was indeed the additional factor 
required for ß-casein expression, we generated 
a mammary cell line that conditionally 
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expressed Flag-tagged DN-Brg1 under the 
control of a tetracycline-repressible 
transactivator. Withdrawal of tetracycline 
from culture medium for 2 days caused a 
dramatic induction of DN-Brg1 expression 
(Fig. 4A) and a significant repression in ß- 
and ?-casein transcription (Fig. 4B, 4C), but 
lactoferrin and GAPDH transcription 
remained unchanged. Thus, the ATPase 
activity of SWI/SNF is necessary for 
transcriptional activation of casein genes. The 
binding of STAT5 and C/EBPß, as well as the 
levels of AcH4 in the ß-casein promoter in 
ECM- and prolactin- treated cells did not 
change significantly in response to DN-Brg1 
expression (Fig. 4D). Western blot analysis 
revealed that DN-Brg1 expression also did not 
affect the nuclear levels of STAT5, C/EBPß 
and GR (data not shown). These results rule 
out the possibility that expression of DN-Brg1 
inhibited ß-casein transcription indirectly by 
repressing the activity of transcription factors, 
and suggest that transcription factor binding 
and histone acetylation in the ß-casein 
promoter are events that take place upstream 
of Brg1 ATPase activity and are not 
dependent on SWI/SNF. In contrast, 
recruitment of RNA polymerase II to the ß-
casein promoter was inhibited by DN-Brg1 
expression, suggesting that its function in 
mediating transcription of casein genes occurs 
downstream of SWI/SNF, and therefore, is 
dependent on ATP-dependent chromatin 
remodeling (Fig. 4D).  
Formation of the SWI/SNF complex was 
shown to occur independently of its ATPase 
activity in NIH 3T3 cells (40,41). We asked 
whether the SWI/SNF complex interacts with 
STAT5, C/EBPß and GR, and whether the 
ATPase activity of Brg1 is necessary for this 
interaction in mammary epithelial cells. 
Protein complexes from ‘tet+’ (no DN-Brg1 
expression) and ‘tet-’ (with DN-Brg1 
expression) cells were immunoprecipitated 
with agarose beads conjugated with anti-
FLAG M2 antibody. The immunoprecipitated 
protein complexes were analyzed by western 
blot using antibodies against STAT5, C/EBPß, 
GR, and lamin B. STAT5 co-
immunoprecipitated with the DN-Brg1 in the 
‘tet-’ cells, but it was absent from the 
immunoprecipitate of ‘tet+’ cells (Fig. 5A). 
We also detected interactions between DN-
Brg1 and GR, and DN-Brg1 and C/EBPß in 
lysates from the ‘tet-’ cells but not ‘tet+’ cells 
(Fig. 5A). However, lamin B was not enriched 
in the co-IP samples from ‘tet-’ cells 
comparing to control (tet+) cells, suggesting 
that the interaction between STAT5, 
C/EBPb, GR and the SWI/SNF complex is 
specific (Fig. 5A). That SWI/SNF is 
associated with GR and C/EBPb has been 
shown (23,25), but the interaction between 
SWI/SNF and STAT5 has not been reported 
previously. To confirm the co-IP results in 
DN-Brg1-expressing cells, we performed a 
co-IP experiment using the parental cells. The 
results showed that endogenous wild type 
SWI/SNF was bound to STAT5 in lrECM- 
and prolactin-treated EpH4 cells but not in 
control cells (Fig. 5B). Therefore, the 
SWI/SNF chromatin remodeling complex may 
be recruited to the ß-casein promoter by 
STAT5, C/EBPß, and/or GR. Several other 
milk proteins, including a-casein, ?-casein, 
whey acidic protein (WAP), and ß-
lactoglobulin have been shown to be regulated 
by ECM and lactogenic hormones (7,42-44). 
The promoter or enhancer elements of these 
genes contain binding sites for STAT5 and 
GR (7,36,45). Interestingly, DN-Brg1 
expression inhibited ?-casein transcription 
significantly, but had no detectable effect on 
transcription of the lactoferrin gene (Fig 4B). 
These data are consistent with the finding that 
the expression of lactoferrin is not dependent 
on the cooperation of ECM and prolactin 
signals in MECs, and that basal transcriptional 
regulation may be different for lactoferrin 
expression (46). These results indicate that 
transcription factors such as STAT5 determine 
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recruitment of the SWI/SNF complex by 
binding to specific promoters to allow 
expression of milk protein genes. 
DISCUSSION 
By necessity, lactation is a tightly regulated 
process during mammary gland development. 
Extracellular and intracellular signals must be 
coordinated precisely and rapidly to ensure 
that milk is produced and delivered in a timely 
fashion after parturition and during suckling. 
Using mammary-specific casein genes as 
markers, we show that laminin and prolactin 
regulate casein expression by inducing 
binding of STAT5 and C/EBPß to their 
promoters, and that both histone acetylation 
and ATP-dependent chromatin remodeling are 
involved in this process (Fig. 5C).  
Previous studies have shown that ECM 
cooperates with prolactin to control ß-
lactoglobulin expression by activating the 
JAK2/STAT5 signal transduction pathway to 
induce STAT5 phosphorylation and its nuclear 
translocation in primary MECs (42,47). Here 
we demonstrate that laminin and prolactin 
cooperatively regulate the binding of STAT5 
to the ß-casein promoter. Upon addition of 
prolactin and lrECM, C/EBPß becomes bound 
to the ß-casein promoter. How these 
extracellular signals regulate C/EBPß activity 
still remains to be determined, but one report 
showed that the nuclear levels of C/EBPß in 
primary rabbit mammary epithelial cells 
increased when these cells were plated on a 
collagen gel (48). We did not observe a 
significant change in the nuclear level of 
C/EBPß in EpH4 cells in response to laminin 
and prolactin treatment. Indeed a luciferase 
reporter gene fused to a C/EBPß-response 
element was not activated by laminin and 
prolactin (data not shown), suggesting that 
C/EBPß DNA-binding activity to the ß-casein 
promoter is enhanced selectively. The binding 
sites of STAT5, C/EBPß, and GR are in close 
proximity to one another within the ß-casein 
promoter, and our co-IP experiments showed 
that these three factors are all associated with 
the SWI/SNF complex. It has been reported 
that STAT5 cooperats with C/EBPß to 
regulate ß-casein promoter activity, and that 
this cooperation is mediated by GR (33). 
Therefore, these factors most likely form a 
protein complex with chromatin remodeling 
enzymes on the ß-casein promoter, and the 
binding of STAT5 may enhance the 
interaction of C/EBPß with the promoter. 
The tight link between eukaryotic gene 
transcription and histone acetylation is now 
firmly established (49,50). Using footprinting 
analysis, previously we showed that whereas 
binding of transcription factors was not 
sufficient to activate the BCE-1 element in 
another mouse epithelial cell line, the 
enhancer element could be activated in the 
absence of ECM upon TSA treatment (20). 
Surprisingly however, the expression of the 
endogenous ß-casein was inhibited by the 
same treatment (21). Using ChIP assays which 
can directly detect the level of histone 
acetylation in a specific chromatin region, we 
demonstrated here that histone acetylation was 
indeed involved in transcriptional activation of 
the endogenous ß-casein gene in functional 
MECs, which is consistent with a recent study 
in HC11 cells (51). We show that TSA 
treatment only slightly increased the basal 
level of ß-casein transcription in 
undifferentiated cells, indicating that histone 
acetylation contributes to, but is not sufficient 
for, induction of endogenous mammary-
specific gene transcription. The controversial 
effects of TSA on the activity of endogenous 
ß-casein gene and exogenous BCE-1 element 
may be due to differences in the nuclear 
environment surrounding these sequences and 
the manner with which each sequence is 
packaged into chromatin. Analysis of global 
histone acetylation patterns has demonstrated 
that gene expression is correlated with histone 
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hyperacetylation in specific chromatin regions 
(17,18). However, treatment with HDAC 
inhibitors only induced expression of less than 
3% of genes in cultured cells (52,53). These 
findings imply that transcription of other 
tissue-specific genes and inducible genes may 
require different types of chromatin 
remodeling.  
ATP-dependent chromatin remodeling 
conducted by the SWI/SNF complex increases 
nucleosome mobility and may uncover a core 
promoter for assembly of a preinitiation 
complex (54). Studies with ATPase-deficient 
Brg1 have demonstrated that the ATPase 
activity of SWI/SNF is required for expression 
of tissue-specific genes in muscle and adipose 
tissues (14,55,56). However, whether the 
expression of mammary-specific genes 
depends on SWI/SNF function was not 
addressed previously. The ChIP assays show 
that the SWI/SNF complex is associated with 
the ß-casein promoter in EpH4 cells upon 
transcriptional activation. This association is 
detected also in primary mammary epithelial 
cells (supplemental Figure 1). Furthermore, 
the ATPase activity of SWI/SNF is necessary 
for transcription of the ß-casein gene. DN-
Brg1 expression leads to a reduction in 
binding of RNA polymerase II, but not the 
levels of STAT5, C/EBPß, and AcH4 in the 
promoter region. Together with the data 
generated from TSA experiments, these 
results suggest that chromatin remodeling 
induced by histone acetylation is not sufficient 
for assembly or stabilization of the RNA 
transcriptional machinery on the ß-casein 
promoter, and that this process depends on 
ATP-dependent chromatin remodeling (Fig. 
5C). Such precise regulation from 
extracellular signals to chromatin structure is 
most likely fundamental to mammary gland 
development and function to ensure control of 
milk protein gene expression during lactation, 
a process that is vital to the offspring’s 
survival. 
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The abbreviates used are: ECM, extracellular matrix; ChIP, chromatin immunoprecipitation; co-
IP, co-immune precipitation; GR, glucocorticoid receptor; HAT, histone acetyltransferases; 
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HDAC, histone deacetylase; TSA, trichostatin A; MEC, mammary epithelial cell; DN-Brg1, 
dominant negative Brg1. 
  
FIGURE LEGENDS 
 
Fig 1. Stat5 phosphorylation and nuclear translocation are activated in EpH4 cells in response to 
ECM and prolactin treatment. (A) ß- and g-casein expression was determined by RT-PCR in 
EpH4 cells cultured for 2 days in GIH (DMEM/F12 supplemented with 5 mg/ml insulin and 1 
mg/ml hydrocortisone). Media alone (Ctrl), GIH + 3 µg/µl prolactin (PRL), GIH + 2% lrECM 
(ECM), and GIH + 3 µg/µl prolactin + 2% lrECM (ECM+PRL). GAPDH cDNA was used as a 
loading control. (B) The ß-casein promoter was cloned into pGL3 luciferase vector, and stably 
transfected into EpH4 cells.  The ß-casein promoter activity was determined by luciferase assays. 
(C, D) Transcription factor levels in the cell lysates (C) and nuclear lysates (D) of EpH4 cells 
were determined by western blotting. 
 
Fig 2. Binding of transcription factors and the SWI/SNF complex to the ß-casein promoter is 
regulated by ECM and prolactin. (A, B) ChIP assays followed by PCR analysis to detect the 
binding of STAT5, C/EBPß, GR, Brg1, and RNA Polymerase II in the ß-casein (A; n=4) and g-
casein (B; n=2) promoters. The PCR results were quantified by AlphaEaseFC software, and the 
values of bound DNA were normalized to input DNA. Fold enrichments were determined by 
dividing the normalized values from treated cells by that of untreated cells, * p<0.05. (C) 
Quantification of ChIP results in EpH4 cells treated with prolactin (PRL), lrECM (ECM), or 
prolactin plus lrECM (PRL+ECM). Graph displays the mean of two experiments. 
 
Fig 3. Histone acetylation contributes to, but is not sufficient to induce ß-casein expression. (A) 
The levels of total histone H3, as well as acetylated histone H4 and H3 in the ß-casein promoter 
were measured by ChIP analysis. The ß-Amylase promoter was used as a control, * p<0.05 (n=3). 
(B) The levels of AcH4 in the ß-casein promoter were determined by ChIP assays in control and 
TSA (80 nM)-treated cells. (C) The ß-casein mRNA levels in undifferentiated EpH4 cells (in 
GIH medium) and differentiated cells (in GIH plus prolactin and lrECM) were measured by 
quantitative RT-PCR after TSA treatment. Graph displays average ± SEM; * p<0.05, *** p<0.01 
(n=4). (D) Protein levels of phosphorylated STAT5, total cell STAT5, C/EBPß and GR were 
analyzed by western blotting after TSA treatment.  
 
Fig 4. DN-Brg1 expression in EpH4 cells suppresses transcription of the ß-casein gene. (A) 
Western blot analysis of DN-Brg1 expression in stably transfected EpH4 cells. (B, C) RT-PCR 
(B) and quantitative PCR (C) analysis of the levels of ß- and g-casein genes in DN-Brg1-
expressing (tet-) and non-expressing (tet+) cells. Graph displays average ± SEM; *** p<0.01 
(n=4). (D) ChIP assays showing the levels of AcH4 and the binding activity of STAT5 and 
C/EBPß in the ß-casein promoter in DN-Brg1-expressing cells. Graph displays mean of three 
experiments, * p<0.05. 
 
Fig 5. STAT5, C/EBPß, and GR interact with DN-Brg1 in EpH4 cells. (A) Interaction between 
transcription factors and DN-Brg1 was determined by co-IP analysis. Total lysates before 
immunoprecipitation were used as input control. (B) Interaction between endogenous Brg1 and 
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STAT5 was detected by co-IP analysis. (C) Model displaying how exposure of mammary 
epithelial cells to ECM and prolactin may induce the recruitment of transcription factors and 
chromatin remodeling enzymes to the ß-casein promoter, and how aberrations in SWI/SNF 
function interfere with RNA polymerase II recruitment. 
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SFig 1: Binding of SWI/SNF complex to the b- and g-casein promoters in primary mammary 
epithelial cells. Primary mammary epithelial cells were isolated from virgin CD-1 mice, and then 
were treated with prolactin and 2 % lrECM for 24 hours. ChIP assay followed by PCR to detect 
the binding of Brg1 in the ß-casein and g-casein promoters.  
